Prescient Therapeutics Limited

Equities

PTX

AU000000PTX3

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 01:51:29 2024-05-06 am EDT			5-day change	1st Jan Change
0.046 ^AUD	0.00%		-11.54%	-25.81%

Mar. 25	Transcript : Prescient Therapeutics Limited - Special Call
Feb. 23	Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Prescient Therapeutics thrilled with additional Orphan Drug Designation status for PTX-100

March 09, 2023 at 03:11 pm EST

(via NewsDirect)

Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke tells Proactive the company has been granted additional Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas (TCL), including cutaneous TCL (CTCL). The designation from the Office of Orphan Products Development at the US Food and Drug Administration, follows ODD for peripheral TCL (PTCL) in 2022. The latest designation broadens the clinical-stage oncology company’s range to all TCLs.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Latest news about Prescient Therapeutics Limited

Transcript : Prescient Therapeutics Limited - Special Call	Mar. 24
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 22	CI
Prescient Therapeutics Receives AU$2.4 Million R&D Tax Rebate; Shares Down 4%	Nov. 27	MT
Prescient Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-24	CI
Prescient Therapeutics Limited Appoints Ellen Feigal to the Board as Non- Executive Director	23-05-14	CI
Prescient Therapeutics Limited Provides an Update on the PTX-100 Phase 1b Expansion Cohort in Relapsed and Refractory T Cell Lymphomas	23-03-15	CI
Prescient Therapeutics Secures US FDA Orphan Drug Designation for Lymphoma Medication; Shares Surge 29%	23-03-08	MT
Prescient Therapeutics Announces FDA Grants Broader Orphan Drug Status to PTX-100 for TCL Indications	23-03-08	CI
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Transcript : Prescient Therapeutics Limited - Shareholder/Analyst Call	22-11-28
Prescient Therapeutics Sees Positive Results in PTX-100 Study	22-10-26	MT
Prescient Therapeutics Limited Announces PTX-100 Trial Update	22-10-24	CI
Prescient Therapeutics Unveils Cancer Drug CellPryme-A; Shares Rise 3%	22-09-22	MT
Prescient Therapeutics Unveils CellPryme-A to Boost Car-T Performance	22-09-22	CI
Transcript : Prescient Therapeutics Limited - Special Call	22-09-08
Prescient Therapeutics, MD Anderson Cancer Center to Develop Blood Cancer Binder for OmniCAR; Shares Rise 3%	22-09-06	MT
Transcript : Prescient Therapeutics Limited - Special Call	22-09-06
Prescient Therapeutics Announces a Strategic Collaboration with the Larger Cancer Centre in the US1, the University of Texas MD Anderson Cancer Center	22-09-06	CI
Prescient Therapeutics Launches $6 Million Share Purchase Plan	22-08-24	MT
Transcript : Prescient Therapeutics Limited - Special Call	22-08-22
Prescient Therapeutics Limited Signs Agreement with Thermo Fisher Scientific to Accelerate OmniCAR Platform Development	22-08-17	CI
Prescient Therapeutics Enters Manufacturing Deal for CAR-T Therapy OmniCAR for Clinical Trials Ahead	22-08-16	MT
Prescient Therapeutics Secures Orphan Drug Designation in US for Lymphoma Drug; Shares Rally 19%	22-07-14	MT
Prescient Therapeutics Secures US Patent for OmniCAR Platform; Shares Rise 6%	22-07-04	MT

Chart Prescient Therapeutics Limited

Duration

Period

More charts

Company Profile

Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is engaged in the development of personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 is a compound with the ability to block a cancer growth enzyme, geranylgeranyl transferase-1 (GGT-1). PTX-100 is in Phase Ib expansion cohort study in T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. PTX-200 is in Phase Ib/II trial in relapsed and refractory AML. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M is a platform for enhancing cell therapies by producing cells with superior phenotypes. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy.

Sector

Biotechnology & Medical Research

Calendar

2024-08-25 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PRESCIENT THERAPEUTICS LIMITED	-25.81%	24.5M
MODERNA, INC.	+22.81%	47.9B
LONZA GROUP AG	+46.56%	41.42B
IQVIA HOLDINGS INC.	-1.88%	40.7B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+11.33%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.27B
BIO-TECHNE CORPORATION	-1.43%	12.15B
MEDPACE HOLDINGS, INC.	+30.73%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.48%	11.99B

Other Biotechnology & Medical Research